Dr. Reddy’s Laboratories has introduced its Difluprednate Ophthalmic Emulsion 0.05%, a therapeutic generic equivalent to Novartis AG’s Durezol (Difluprednate Ophthalmic Emulsion 0.05%) in the U.S. market.
A topical corticosteroid, the product is indicated for treatment of inflammation and pain associated with ocular surgery; and endogenous anterior uveitis. The Durezol brand and generic had U.S. sales of approximately $40 million MAT for the most recent 12 months ending in Nov 2022, the company said citing IQVIA.
Dr. Reddy’s said its Difluprednate Ophthalmic Emulsion 0.05% is available in 5 ml bottles in case packs of 24.
